The Clinical Question: Is it time to re-challenge anti-EGFR in mCRC? has been discussed by Assoc. Prof. Gerald Prager, Dr Dominik Modest and Dr Andrea Sartore-Bianchi.
The Clinical Question: Is it time to re-challenge anti-EGFR in mCRC? has been discussed by Assoc. Prof. Gerald Prager, Dr Dominik Modest and Dr Andrea Sartore-Bianchi.
Andrea Sartore-Bianchi is the Director of the Division of Clinical Research and Innovation at Grande Ospedale Metropolitano Niguarda in Milano, Italy, and Associate Professor of Oncology at the University of Milano. He received his MD and postgraduate degree in Oncology at the University of Pavia, Italy, and subsequently conducted preclinical research at Brown University, Providence, RI, USA.
His main clinical and research interests include precision oncology and the treatment of gastrointestinal cancers, particularly colorectal carcinomas, focusing on biomarkers of sensitivity/resistance to targeted therapies. He is principal and co-investigator in Phase I-III clinical trials for solid tumours and carried out initial studies paving the way for the use of RAS and Her2 as tumor tissue/ctDNA biomarkers in colorectal cancer. He has published 200 peer-reviewed articles in various medical journals with a H-index of 62 (Scopus).
Amgen, Bayer, Sanofi and Servier Pharmaceuticals.
Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer
Experți de renume din domeniul medical își împărtășesc perspectivele. Navigați în secțiuni pentru a selecta un episod al podcastului
Improving the survival of patients with relapsed/refractory multiple myeloma
Expert insights into personalised treatment strategies in BRAF-mutated NSCLC
Chemotherapy strategies that matter
Insights and support for patients